House Passage of FDA User Fee Reauthorization Makes Cancer Patients a Priority
The House advanced legislation to reauthorize and expand the FDA's user fee programs that maintain a strong partnership between the FDA and industry, with the goal of bringing pharmaceutical drugs and devices to the market, and making them accessible to patients, as expeditiously as possible.